These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 34794404

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD, de Hond A, Degeling K, Punt CJA, Koopman M, Uyl-de Groot CA, Versteegh MM, van Oijen MGH.
    Health Qual Life Outcomes; 2020 Jul 20; 18(1):240. PubMed ID: 32690011
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F, Doble B, CANCER 2015 Consortium.
    Med Decis Making; 2018 Nov 20; 38(8):954-967. PubMed ID: 30226101
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B, Lorgelly P.
    Qual Life Res; 2016 Apr 20; 25(4):891-911. PubMed ID: 26391884
    [Abstract] [Full Text] [Related]

  • 10. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
    Yang F, Wong CKH, Luo N, Piercy J, Moon R, Jackson J.
    Eur J Health Econ; 2019 Nov 20; 20(8):1195-1206. PubMed ID: 31338698
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D.
    Value Health; 2009 Nov 20; 12(8):1151-7. PubMed ID: 19558372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE.
    Health Qual Life Outcomes; 2014 Mar 11; 12():35. PubMed ID: 24618388
    [Abstract] [Full Text] [Related]

  • 16. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
    Kim EJ, Ko SK, Kang HY.
    Qual Life Res; 2012 Sep 11; 21(7):1193-203. PubMed ID: 22012023
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A, Soare A, Chevrou-Severac H, Myren KJ, Murata T, Longworth L.
    Appl Health Econ Health Policy; 2022 Jan 11; 20(1):119-131. PubMed ID: 34554442
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
    Huang D, Zeng D, Tang Y, Jiang L, Yang Q.
    Qual Life Res; 2024 Feb 11; 33(2):491-505. PubMed ID: 37938402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.